-
Product Insights
New![]()
Net Present Value Model: Sanofi’s Fitusiran
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Sanofi’s Rilzabrutinib
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Sanofi’s Tolebrutinib
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Sanofi’s Itepekimab
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Sanofi’s Amlitelimab
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Sanofi’s Venglustat malate
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Sanofi’s Tusamitamab ravtansine
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Company Insights
![]()
Sanofi S.A – Digital Transformation Strategies
Sanofi Digital Transformation Strategies Report Overview Sanofi S.A. (Sanofi) has been focusing on using artificial intelligence, cloud, virtual reality and big data to digitally transform its operations. The annual ICT spending of Sanofi was estimated at $1.1 billion for 2023. A major share of this spending is earmarked for acquiring software, ICT services and consulting services from vendors. Sanofi is a France-based multinational life sciences company. It focuses on the research & development, manufacture, and marketing of a wide range...
-
Product Insights
New![]()
Net Present Value Model: Sanofi’s Efanesoctocog alfa
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Company Insights
![]()
Sanofi S.A. – Company Overview and Analysis, 2023 Update
"Company Analysis 2023: Sanofi S.A.", reports key findings as of 4th August, 2023 based on market analysis and brand diversification by industry and geography. Sanofi S.A. (Sanofi) is a French healthcare company that develops and markets a wide range of medications. The company is also a manufacturer and marketer of consumer health, cosmetics & toiletries, pet care, and non-alcoholic beverages. Sanofi has presence across all the regions worldwide with major business concentrated in West Europe, which accounted for 25% of...
-
Product Insights
New![]()
Net Present Value Model: AstraZeneca Plc’s Danicopan
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Sector Analysis
![]()
Viscosupplementation Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
Viscosupplementation Market Overview The Viscosupplementation market size was valued at $1.43 billion in 2022. Viscosupplementation is the process by which the synovial fluid at the joints is replaced by a Hyaluronate preparation which has viscous properties like the natural synovial fluid. Viscosupplementation is used for the treatment of osteoarthritis of the knee and other joints. Other joints include the hip, shoulder, ankle, elbow, wrist, hand and foot. Viscosupplementation Market Outlook, 2022-2033 ($ Billion) Buy Full Report for More Insights into...
-
Product Insights
New![]()
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Clinical Trials Overview The Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trial report consists of 3259 trials. The report provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trial scenario. The report provides top-line data relating to the clinical trials on Acute Lymphocytic Leukemia. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of...
-
Product Insights
![]()
Lonza/ Sanofi – Ibex Solutions Biopharmaceutical Factory – Valais
Equip yourself with the essential tools needed to make informed and profitable decisions with our Lonza/ Sanofi - Ibex Solutions Biopharmaceutical Factory - Valais report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
![]()
Sanofi – Beijing Insulin Production Base Upgrade – Beijing
Equip yourself with the essential tools needed to make informed and profitable decisions with our Sanofi – Beijing Insulin Production Base Upgrade – Beijing report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Acquire a thorough understanding of the...
-
Product Insights
![]()
Queensland Gov/ Sanofi – Translational Science Hub – Queensland
Equip yourself with the essential tools needed to make informed and profitable decisions with our Queensland Gov/ Sanofi - Translational Science Hub - Queensland report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SPI-62 in Cushing’s Syndrome
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SPI-62 in Cushing’s Syndrome Drug Details: Concomitant therapy of SPI-62 and next generation corticosteroid is...
-
Product Insights
New![]()
Net Present Value Model: BioNTech SE’s BNT-113
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
![]()
Meningitis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Meningitis Clinical Trials Market Report Overview The Meningitis clinical trial market research report provides an overview of Meningitis Clinical trials scenario. This report provides top line data relating to the clinical trials on Meningitis. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides...
-
Product Insights
![]()
Myelodysplastic Syndrome Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Myelodysplastic Syndrome Clinical Trials Overview The Myelodysplastic syndrome clinical trial report consists of 3228 trials. The report provides an overview of the Myelodysplastic syndrome clinical trials scenario. The report provides top-line data relating to the clinical trials on Myelodysplastic syndrome. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.